Research Analysts Issue Forecasts for PepGen Q1 Earnings

PepGen Inc. (NASDAQ:PEPG) – Equities research analysts at Wedbush boosted their Q1 2025 earnings per share (EPS) estimates for PepGen in a report issued on Monday, February 24th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($0.54) per share for the quarter, up from their prior forecast of ($0.65). Wedbush currently has a “Outperform” rating and a $12.00 target price on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. Wedbush also issued estimates for PepGen’s Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.22) EPS, FY2026 earnings at ($2.11) EPS, FY2027 earnings at ($1.91) EPS, FY2028 earnings at ($1.50) EPS and FY2029 earnings at ($0.10) EPS.

PepGen (NASDAQ:PEPG) last released its earnings results on Monday, February 24th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.13.

Several other brokerages have also recently commented on PEPG. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of PepGen in a research report on Monday. Bank of America downgraded shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price target on the stock. in a research note on Monday, December 16th.

PepGen Trading Down 10.5 %

PEPG stock opened at $1.53 on Thursday. PepGen has a 12-month low of $1.16 and a 12-month high of $19.30. The business’s 50-day moving average is $2.41 and its 200 day moving average is $5.75. The stock has a market cap of $49.87 million, a price-to-earnings ratio of -0.51 and a beta of 1.53.

Hedge Funds Weigh In On PepGen

A number of institutional investors have recently added to or reduced their stakes in PEPG. Jane Street Group LLC increased its stake in shares of PepGen by 29.1% in the 3rd quarter. Jane Street Group LLC now owns 27,748 shares of the company’s stock worth $237,000 after acquiring an additional 6,254 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of PepGen in the fourth quarter valued at about $26,000. Northern Trust Corp increased its position in PepGen by 5.4% during the fourth quarter. Northern Trust Corp now owns 157,038 shares of the company’s stock worth $595,000 after purchasing an additional 7,984 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in PepGen in the 3rd quarter valued at about $95,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of PepGen by 26.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 57,102 shares of the company’s stock worth $216,000 after buying an additional 11,870 shares during the last quarter. Hedge funds and other institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.